top of page

A Look at the Pharmaceutical Cannabinoid Companies Featured at Benzinga’s Healthcare Conference

Companies developing pharmaceutical cannabinoids have been creeping up on the pharmaceutical sector as new advancements in researching and manufacturing man-made compounds are made. Components of these cannabinoids are being used in treatments for cancers and other illnesses, and are gaining momentum in the public sector.

Benzinga’s Healthcare Small Cap Conference, which wraps up today, gathers Small Cap companies, investors, and traders to discuss investment opportunities in the sector. Presenting on the panel titled ‘Pharmaceutical Cannabinoids and their Impact on Treatments for Complex Diseases’ were InMed, Skye Bioscience Inc., Cardiol Therapeutics, Inc., and Can-Fite BioPharma Ltd.

InMed Pharmaceuticals (NASDAQ: IMD) InMed Pharmaceuticals (“InMed”) is a clinical-stage pharmaceutical company using medicines bio-identical to cannabinoids used to treat diseases with unmet medical needs, such as skin and ocular diseases. The company has been focused on developing IntegraSyn™, its manufacturing system for these biosynthetic cannabinoids, in order to meet the demand needed for cannabinoid therapeutics.

As opposed to competitors which may only be focused on the use of THC and CBD therapeutics, InMed also prides itself in its research in the many other cannabinoids that can be used to treat diseases.

InMed currently has two drugs in development, INM-755 and INM-088, for the treatment of the conditions listed above. The development of these drugs is being carried out in InMed’s British Columbia-based pharmaceutical company which it acquired in 2014.

Skye Bioscience Inc. (OTCMKTS: SKYE) Skye Bioscience Inc. (“SKYE”) is developing proprietary cannabinoids to treat glaucoma and a variety of other diseases. It currently has two drugs in development: THCVHS, a proprietary prodrug of THC, and CBDVHS, a proprietary analog of CBD. The former was recently selected for presentation with its research partner, The University of Mississippi, at the American Association of Pharmaceutical Scientists Meeting (AAPS) PharmSci 360 taking place in late October.

Cardio Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) Cardiol Therapeutics Inc. (“Cardiol”) is a clinical-stage biotechnology company developing anti-inflammatory therapies to treat cardiovascular disease. Its lead clinical product, CardiolRx™, received FDA clearance for its Investigational New Drug (IND) application. The trial for CardiolRx™investigates its role in treating hospitalized COVID-19 patients with prior cardiovascular history. The pharmaceutically-produced oral formulation contains high-concentration cannabinoids and is THC-free.

Cardio is partnered with several reputable institutions including The Houston Methodist DeBakey Heart & Vascular Center, University of Alberta, and TecSalud del Tecnológico de Monterrey.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) Can-Fite BioPharma Ltd. (“Can-Fite”) is an Isreali biopharmaceutical company developing proprietary, clinical-stage drugs to address inflammatory, liver, and metabolic diseases. The company’s lead drug candidate, Piclidenoson, is in various stages of clinical development for treatment of both psoriasis and moderate COVID-19.

Can-Fite also recently entered a $3B agreement with France-based veterinary and biotech company VetBiolix to develop Piclidenoson for the treatment of osteoarthritis in cats and dogs. Can-Fite has also gained media attention for its research and development of the A3 Adenosine Receptor, used as a therapeutic target and biological predictive marker.

Want Exclusive Stock Reports?

Thanks for submitting!

bottom of page